09 - 12
Dec 2023
ASH 2023
World’s largest network supporting clinical and scientific hematology research.
Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
Assessment of Minimal Clinically Important Difference in Patient-Reported Myelofibrosis-Associated Symptoms Using an Anchor-Based Analysis Based on MANIFEST Arm 3 Data
MorphoSys is providing the data presented at medical congresses as part of scientific exchange. The scientific information may include data/information on investigational use(s) of compounds/drugs of which the efficacy and safety have not yet been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of MorphoSys’ products. Copies of congress presentations may not be reproduced without written permission from the congress and the authors.
Sie verlassen nun die Website MorphoSys.com. Dieser Link führt Sie zu einer anderen Website. Sie allein sind für Ihre Interaktionen mit dieser Website verantwortlich.
Möchten Sie fortfahren ?
Are you a U.S. resident? This portion of the MorphoSys website is intended for U.S. residents only. It is not for individuals living in Germany or other European Union member states.
Möchten Sie fortfahren ?
MorphoSys is providing the data presented at medical congresses as part of scientific exchange. The scientific information may include data/information on investigational use(s) of compounds/drugs of which the efficacy and safety have not yet been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of MorphoSys’ products. Copies of congress presentations may not be reproduced without written permission from the congress and the authors.
Are you a U.S. resident? This portion of the MorphoSys website is intended for U.S. residents only. It is not for individuals living in Germany or other European Union member states.